• Halozyme CEO Helen Torley reported option exercises totaling 60,000 shares from Sept. 9-11, 2026 at USD 18.41.
• Disposed of 60,000 shares over the same period at weighted-average prices near USD 107 per share.
• Beneficial ownership of common stock ended at 767,780 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000119), on September 11, 2026, and is solely responsible for the information contained therein.